FDA Moves to Pull Controversial Preterm Birth Drug From the Market

The FDA is calling for withdrawal of the approval for the injectable agent 17α-hydroxyprogesterone caproate (17-OHPC; Makena) for pregnant women with a history of at least one spontaneous preterm birth, stating that the drug is ineffective in reducing preterm births, as well as other poor neonatal outcomes, according to briefing documents released ahead of a 3-day advisory committee meeting.

On October 17, the Obstetrics, Reproductive and Urologic Drugs Advisory Committee will meet to discuss whether the drug and its generics should remain on the market.

“Makena has not been shown to improve neonatal outcomes from premature birth, is no longer shown to be effective for its approved use, and has known risks,” wrote FDA staff. “For these and other reasons … Makena should be withdrawn from the market.”

The documents paint the picture of why an FDA advisory committee voted to pull accelerated approval for the drug back in 2019.

Covis Pharma, which manufactures the drug, has taken the opposite position, stating in their own briefing documents that “there is no reason to deprive women of the only available FDA-approved treatment to reduce the risk of preterm birth in high-risk women while an additional study is conducted.”

The agency countered that the continued marketing of the drug in the “absence of demonstration of benefit incurs false hopes,” and represents an unnecessary burden on patients and healthcare resources. As an example, they noted that women receive up to 20 injections of 17-OHPC during pregnancy.

The FDA initially approved 17-OHPC in 2011 to reduce the risk of preterm birth before 37 weeks of pregnancy among women who had a history of spontaneous preterm birth. The drug was approved under the accelerated approval pathway, which allows the agency to expedite the approval process for certain medications based on a surrogate endpoint thought to predict clinical benefit.

The initial approval was based on clinical trial results that found that women who received a 250-mcg injection of 17-OHPC had a significantly lower risk of delivering before 37 weeks of pregnancy compared with those in a placebo arm. However, because the risk reduction in preterm births did not signify a direct clinical benefit to neonates born prematurely, the FDA required a postmarketing confirmatory trial.

The FDA’s position to pull 17-OHPC and its generics from the market is based on results from this confirmatory trial, which contradicted the initial findings. In the PROLONG study, which included 1,700 patients, 17-OHPC did not have a statistically significant effect on preterm births before 35 weeks’ gestation (relative risk [RR] 0.95, 95% CI 0.71-1.26) or a neonatal composite index that included outcomes such as death, respiratory distress syndrome, bronchopulmonary dysplasia, and sepsis, among others (RR 1.05, 95% CI 0.68-1.61).

In addition, the drug did not improve the rate of preterm births before 32 weeks’ gestation or 37 weeks’ gestation (RR 1.06, 95% CI 0.88-1.28) — the latter of which was the primary endpoint of the trial that supported accelerated approval. The drug also did not have a positive effect on subpopulations, including Black women, who have an increased risk of delivering prematurely. Covis, however, has stated that the PROLONG trial enrolled fewer Black women, which may have subjected its results to selection bias.

In their briefing materials, FDA staff noted that the benefit-risk calculation for 17-OHPC was not favorable, since the medication is not only ineffective, but also carries risks for adverse events such as blood clots or depression. Additionally, a recent observational study found that babies exposed to 17-OHPC in utero had a greater risk of cancer later in life.

“Failing to withdraw Makena would maintain FDA approval of a drug that, based on all available evidence, has not been shown to be more effective than, but is riskier than, no treatment,” FDA staff wrote.

Covis has called on the FDA to maintain approval while additional studies are conducted, pointing out that pulling the drug’s approval could have negative repercussions on health outcomes in populations at risk for preterm birth. However, the FDA has continued to uphold its position to withdraw approval while future research is pursued, arguing that it will be difficult to enroll patients in a study for a drug that is already available.

  • Amanda D’Ambrosio is a reporter on MedPage Today’s enterprise & investigative team. She covers obstetrics-gynecology and other clinical news, and writes features about the U.S. healthcare system. Follow

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
California LGMA announces romaine testing  study thumbnail

California LGMA announces romaine testing study

The California LGMA (Leafy Greens Marketing Agreement) has announced the initiation of a 2-year food safety study called “Romaine Test & Learn.”  Approved unanimously by the LGMA Advisory Board, the study aims to collect and analyze pathogen test data for romaine lettuce from LGMA members, encompassing both pre-harvest and post-harvest testing. Jan Berk, LGMA Chair
Read More
Can MSG Be a Salt Substitute? thumbnail

Can MSG Be a Salt Substitute?

MENGONSUMSI asupan garam berlebihan bisa membuat Anda kelebihan natrium. Namun Anda bisa melakukan beberapa cara untuk mengendalikan asupan garam, salah satunya membuat makanan dengan cita rasa umami. Jika tubuh mengalami kelebihan natrium, berisiko menimbulkan masalah kesehatan. Terutama bagi para penderita hipertensi, karena memicu sederet penyakit degeneratif. Ahli Gizi & Dosen di Fakultas Kesehatan Masyarakat Universitas…
Read More
Weather: Cloudy today, rain overnight thumbnail

Weather: Cloudy today, rain overnight

This advertisement has not loaded yet, but your article continues below. Author of the article: Robert Cross FILE: A runner makes her way along Dow's Lake under cloudy skies. Photo by Wayne Cuddington /POSTMEDIA Article content Mainly cloudy Sunday with winds becoming west 20 km/h gusting to 40 this morning. The high temperature will reach…
Read More
Corona’da Aşk Evrildi mi, Devrildi mi? thumbnail

Corona’da Aşk Evrildi mi, Devrildi mi?

Her geçen gün gözlerimizi kapatıyor, ‘Corona’dan önce bu zamanlar acaba ne yapıyordum’ diye düşünüyoruz. Tatil, eğitim, alışveriş, eğlenmek için yaptıklarımızı, kısaca her şeyi gözden geçiriyoruz. Peki ya ilişkilerimiz? Coronavirüs ile savaşırken aşk evrildi mi, devrildi mi?Dr. Esra Uğurlu KoçerPsikiyatri UzmanıAşk, hayatın her döneminde vazgeçilmeyen en temel duygulardan biri… Oturup düşünüldüğünde mantıklı bir neden-sonuç ilişkisine bağlanamazsa…
Read More
Journalists Unpack Facility School Closures and Federal Investment in Crisis Hotlines thumbnail

Journalists Unpack Facility School Closures and Federal Investment in Crisis Hotlines

KFF Health News Colorado correspondent Rae Ellen Bichell discussed Colorado facility schools on Rocky Mountain Community Radio on May 12. Click here to hear Bichell on Rocky Mountain Community Radio Read Bichell’s “Students in Rural Colorado Are Left Without Options as Specialized Schools Close” KFF Health News former senior editor Andy Miller discussed lead contamination
Read More
Childhood routine jabs pick up after COVID backslide: UN thumbnail

Childhood routine jabs pick up after COVID backslide: UN

Credit: Unsplash/CC0 Public Domain Routine vaccination of children is picking up again after a dramatic drop during the COVID-19 crisis, the United Nations said Tuesday, warning that dangerous gaps remain. Four million more children received routine childhood vaccines last year than in 2021, according to data published by the UN health and children's agencies. "That's
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

Total
0
Share